Overcoming Adherence Issues in Ulcerative Colitis

Overview

Journal Gastroenterol Hepatol (N Y)

Specialty Gastroenterology

Date 2011 Oct 1

PMID 21960790

Citations 7

Authors

Sunanda V Kane

Affiliations

Soon will be listed here.

Abstract

Ulcerative colitis (UC) is a chronic condition requiring lifelong medication to minimize the incidence of symptomatic flares. Nevertheless, studies have shown that a large proportion of patients are nonadherent to their prescribed therapeutic regimen. This review examines studies of patient adherence to 5-aminosalicylic acid (5-ASA) therapy in real world settings and considers the reasons that patients do not adhere to medication. Patients offer numerous reasons for not taking medication as prescribed; however, neither clinical nor community studies have consistently identified the same groups of patients as being high risk for poor adherence. Indeed, the problem of nonadherence is complex and requires a combination of strategies to be improved. Physicians, physician assistants, and nurse practitioners need to take the time to explain the importance of continual therapy, even when patients feel well, and should engage patients in a discussion to aid in the understanding of their nonadherence. Then, healthcare providers can determine how to best amend the regimen to improve adherence. As taking several tablets several times daily may be confusing or difficult for patients, higher strength 5-ASA formulations that require fewer daily doses have the potential to enhance patient adherence as part of an overall management strategy.

Citing Articles

Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition.

Akyuz F, An Y, Begun J, Aniwan S, Bui H, Chan W Intest Res. 2024; 23(1):37-55.

PMID: 39492666 PMC: 11834365. DOI: 10.5217/ir.2024.00089.

Etrolizumab as an induction and maintenance therapy for ulcerative colitis: A systematic review and meta-analysis of randomized controlled trials.

Saleh O, Abuelazm M, Mohamed I, Ramadan A, Assaf M, Alzoubi A JGH Open. 2024; 8(4):e13056.

PMID: 38572328 PMC: 10986297. DOI: 10.1002/jgh3.13056.

Predictive factors of relapse after dose reduction of oral 5-aminosalicylic acid in patients with ulcerative colitis in the remission phase.

Madarame A, Fukuzawa M, Yamauchi Y, Kono S, Sugimoto A, Yamaguchi H PLoS One. 2021; 16(8):e0255620.

PMID: 34347848 PMC: 8336875. DOI: 10.1371/journal.pone.0255620.

Ulcerative colitis in the postpartum period.

Chiba M, Tsuji T, Komatsu M, Watanabe H, Takahashi M Autops Case Rep. 2020; 10(4):e2020187.

PMID: 33344315 PMC: 7703396. DOI: 10.4322/acr.2020.187.

Higher education, professional occupation, and upper socioeconomic status are associated with lower adherence to medications in patients with inflammatory bowel disease.

Tomar S, Kedia S, Singh N, Upadhyay A, Kamat N, Bopanna S JGH Open. 2019; 3(4):302-309.

PMID: 31406923 PMC: 6684767. DOI: 10.1002/jgh3.12160.

References

Brunner M, Assandri R, Kletter K, Tschurlovits M, Corrado M, Villa R . Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment Pharmacol Ther. 2003; 17(3):395-402. DOI: 10.1046/j.1365-2036.2003.01445.x. View

Kane S, Cohen R, Aikens J, Hanauer S . Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001; 96(10):2929-33. DOI: 10.1111/j.1572-0241.2001.04683.x. View

Loftus Jr E, Silverstein M, Sandborn W, Tremaine W, Harmsen W, Zinsmeister A . Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut. 2000; 46(3):336-43. PMC: 1727835. DOI: 10.1136/gut.46.3.336. View

Lichtenstein G, Kamm M, Boddu P, Gubergrits N, Lyne A, Butler T . Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007; 5(1):95-102. DOI: 10.1016/j.cgh.2006.10.025. View

Kripalani S, Yao X, Haynes R . Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007; 167(6):540-50. DOI: 10.1001/archinte.167.6.540. View

Sewitch M, Abrahamowicz M, Barkun A, Bitton A, Wild G, Cohen A . Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol. 2003; 98(7):1535-44. DOI: 10.1111/j.1572-0241.2003.07522.x. View

Kane S, Huo D, Aikens J, Hanauer S . Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003; 114(1):39-43. DOI: 10.1016/s0002-9343(02)01383-9. View

Hanauer S, Sandborn W, Kornbluth A, Katz S, Safdi M, Woogen S . Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005; 100(11):2478-85. DOI: 10.1111/j.1572-0241.2005.00248.x. View

Carter M, Lobo A, Travis S . Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004; 53 Suppl 5:V1-16. PMC: 1867788. DOI: 10.1136/gut.2004.043372. View

10.

Moody G, Jayanthi V, Probert C, Mac Kay H, Mayberry J . Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol. 1996; 8(12):1179-83. DOI: 10.1097/00042737-199612000-00009. View

11.

Kane S, Huo D, Magnanti K . A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol. 2004; 1(3):170-3. DOI: 10.1053/cgh.2003.50025. View

12.

Kovvali G, Das K . Molecular mimicry may contribute to pathogenesis of ulcerative colitis. FEBS Lett. 2005; 579(11):2261-6. DOI: 10.1016/j.febslet.2005.02.073. View

13.

Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J . Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2000; 14(2):145-53. DOI: 10.1046/j.1365-2036.2000.00698.x. View

14.

Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T . Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology. 1998; 115(2):357-69. DOI: 10.1016/s0016-5085(98)70202-1. View

15.

Riley S, Mani V, GOODMAN M, Lucas S . Why do patients with ulcerative colitis relapse?. Gut. 1990; 31(2):179-83. PMC: 1378376. DOI: 10.1136/gut.31.2.179. View

16.

Schmidt C, Stallmach A . Etiology and pathogenesis of inflammatory bowel disease. Minerva Gastroenterol Dietol. 2005; 51(2):127-45. View

17.

Davis T, Wolf M, Bass 3rd P, Thompson J, Tilson H, Neuberger M . Literacy and misunderstanding prescription drug labels. Ann Intern Med. 2006; 145(12):887-94. DOI: 10.7326/0003-4819-145-12-200612190-00144. View

18.

van Hees P, van Tongeren J . Compliance to therapy in patients on a maintenance dose of sulfasalazine. J Clin Gastroenterol. 1982; 4(4):333-6. DOI: 10.1097/00004836-198208000-00008. View

19.

Kornbluth A, Sachar D . Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004; 99(7):1371-85. DOI: 10.1111/j.1572-0241.2004.40036.x. View

20.

Qureshi A, Cohen R . Mesalamine delivery systems: do they really make much difference?. Adv Drug Deliv Rev. 2004; 57(2):281-302. DOI: 10.1016/j.addr.2004.08.008. View